A Study to Evaluate the Effect of AZD8154 Administered Via Nebulizer Once Daily in Subjects With Mild Allergic Asthma Challenged With an Inhaled Allergen

Summary

This is a Phase IIa, double blind, randomized, parallel group, placebo controlled multi centre study to evaluate the effect of AZD8154 (administered via nebulizer daily \[QD\]) on allergen-induced inflammation in subjects with mild allergic asthma challenged with an inhaled allergen. Approximately 36 subjects who meet all eligibility criteria will be randomized (1:1) to receive either AZD8154 or placebo.

Timeline

Start

2020-02-06

Primary completion

2021-11-10

Completion

2021-11-10

Outcome

Outcome not reported

Stopped: “The reason is: emerging pre-clinical toxicology findings.”

Drugs

Indications